Thyroid Disorders and Prognosis in Chronic Heart Failure: A Long-Term Follow-Up Study

Author(s): Massimo Iacoviello*, Giuseppe Parisi, Margherita I. Gioia, Dario Grande, Caterina Rizzo, Pietro Guida, Francesco Lisi, Vito A. Giagulli, Brunella Licchelli, Francesca Di Serio, Edoardo Guastamacchia, Vincenzo Triggiani

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

Volume 20 , Issue 3 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Thyroid disorders may have a negative impact on the prognosis of patients affected by chronic heart failure (CHF).

Objective: The aim of the current study was to evaluate the prognostic role of all thyroid disorders over a long term follow-up in a single centre large sample of CHF outpatients.

Methods: In all patients, the function of the thyroid was evaluated at the enrolment and during the follow- up. On the basis of free triiodothyronine (T3), free thyroxine (fT4) and thyroid-stimulating hormone (TSH) serum levels, patients were classified into one of the following four categories: euthyroid subjects, patients affected by hypothyroidism, low T3 (LT3) syndrome and hyperthyroidism. During the follow-up, death for all causes was assessed as primary end-point, whereas time to the first hospitalization for heart failure worsening was the secondary end-point analyzed.

Results: Among 762 patients, 190 patients were affected by hypothyroidism (Hypo). LT3 syndrome was diagnosed in 15 patients and 59 patients were affected by hyperthyroidism (Hyper). During a long term follow-up (5.1±3.7 years), 303 patients died. Patients with Hypo showed an increased risk of death as well as of hospitalization due to heart failure worsening at univariate regression analysis. At multivariate regression analysis, Hypo remained associated with hospitalization after correction for age >75 years, ischemic aetiology, diabetes, therapy with ACE-inhibitors or ARBs, therapy with betablockers and with aldosterone antagonists, NYHA class 3, systolic arterial pressure <95 mmHg, left ventricular ejection fraction <30%, estimated glomerular filtration rate <60 ml/min, hyponatremia and NTproBNP> 1000 pg/ml. At multivariate analysis, the independent association with death was significant only for the subgroup of patients with TSH >10 mIU/L. LT3 was independently associated with both heart failure hospitalization and death, whereas Hyper was not associated with any of the two considered end-points.

Conclusion: Hypo is associated with a worse prognosis over a long-term follow-up. The association with heart failure hospitalization is not dependent on the baseline TSH levels, whereas the association with death is significant only when TSH >10 mIU/L. Finally, Hyper does not have any association with a worse prognosis.

Keywords: Hypothyroidism, hyperthyroidism, chronic heart failure, prognosis, low T3 Syndrome, thyroid hormones.

[1]
Klein, I.; Danzi, S. Thyroid disease and the heart. Circulation, 2007, 116(15), 1725-1735.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.678326] [PMID: 17923583]
[2]
Rizzo, C.; Gioia, M.I.; Parisi, G.; Triggiani, V.; Iacoviello, M. Dysthyroidism and chronic heart failure: pathophysiological mechanisms and therapeutic approaches. Adv. Exp. Med. Biol., 2018, 1067, 239-253.
[http://dx.doi.org/10.1007/5584_2017_132] [PMID: 29235066]
[3]
Triggiani, V.; Angelo Giagulli, V.; De Pergola, G.; Licchelli, B.; Guastamacchia, E.; Iacoviello, M. Mechanisms explaining the influence of subclinical hypothyroidism on the onset and progression of chronic heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2016, 16(1), 2-7.
[http://dx.doi.org/10.2174/1871530316666151218151319] [PMID: 26680772]
[4]
Pingitore, A.; Landi, P.; Taddei, M.C.; Ripoli, A.; L’Abbate, A.; Iervasi, G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am. J. Med., 2005, 118(2), 132-136.
[http://dx.doi.org/10.1016/j.amjmed.2004.07.052] [PMID: 15694896]
[5]
Kozdag, G.; Ural, D.; Vural, A.; Agacdiken, A.; Kahraman, G.; Sahin, T.; Ural, E.; Komsuoglu, B. Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur. J. Heart Fail., 2005, 7(1), 113-118.
[http://dx.doi.org/10.1016/j.ejheart.2004.04.016] [PMID: 15642542]
[6]
Iacoviello, M.; Guida, P.; Guastamacchia, E.; Triggiani, V.; Forleo, C.; Catanzaro, R.; Cicala, M.; Basile, M.; Sorrentino, S.; Favale, S. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr. Pharm. Des., 2008, 14(26), 2686-2692.
[http://dx.doi.org/10.2174/138161208786264142] [PMID: 19006851]
[7]
Triggiani, V.; Iacoviello, M.; Monzani, F.; Puzzovivo, A.; Guida, P.; Forleo, C.; Ciccone, M.M.; Catanzaro, R.; Tafaro, E.; Licchelli, B.; Giagulli, V.A.; Guastamacchia, E.; Favale, S. Incidence and prevalence of hypothyroidism in patients affected by chronic heart failure: role of amiodarone. Endocr. Metab. Immune Disord. Drug Targets, 2012, 12(1), 86-94.
[http://dx.doi.org/10.2174/187153012799278947] [PMID: 22214334]
[8]
Chen, S.; Shauer, A.; Zwas, D.R.; Lotan, C.; Keren, A.; Gotsman, I. The effect of thyroid function on clinical outcome in patients with heart failure. Eur. J. Heart Fail., 2014, 16(2), 217-226.
[http://dx.doi.org/10.1002/ejhf.42] [PMID: 24464626]
[9]
Mitchell, J.E.; Hellkamp, A.S.; Mark, D.B.; Anderson, J.; Johnson, G.W.; Poole, J.E.; Lee, K.L.; Bardy, G.H. Thyroid function in heart failure and impact on mortality. JACC Heart Fail., 2013, 1(1), 48-55.
[http://dx.doi.org/10.1016/j.jchf.2012.10.004] [PMID: 24159562]
[10]
Ning, N.; Gao, D.; Triggiani, V. Prognostic role of hypothyroidism on Heart failure. Medicine (Baltimore), 2015, 94, 1159.
[http://dx.doi.org/10.1097/MD.0000000000001159]
[11]
Gencer, B.; Collet, T.H.; Virgini, V.; Bauer, D.C.; Gussekloo, J.; Cappola, A.R.; Nanchen, D.; den Elzen, W.P.; Balmer, P.; Luben, R.N.; Iacoviello, M.; Triggiani, V.; Cornuz, J.; Newman, A.B.; Khaw, K.T.; Jukema, J.W.; Westendorp, R.G.; Vittinghoff, E.; Aujesky, D.; Rodondi, N. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation, 2012, 126(9), 1040-1049.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.096024] [PMID: 22821943]
[12]
Cooper, D.S.; Biondi, B. Subclinical thyroid disease. Lancet, 2012, 379(9821), 1142-1154.
[http://dx.doi.org/10.1016/S0140-6736(11)60276-6] [PMID: 22273398]
[13]
Rodondi, N.; den Elzen, W.P.J.; Bauer, D.C.; Cappola, A.R.; Razvi, S.; Walsh, J.P.; Asvold, B.O.; Iervasi, G.; Imaizumi, M.; Collet, T.H.; Bremner, A.; Maisonneuve, P.; Sgarbi, J.A.; Khaw, K.T.; Vanderpump, M.P.; Newman, A.B.; Cornuz, J.; Franklyn, J.A.; Westendorp, R.G.; Vittinghoff, E.; Gussekloo, J. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 2010, 304(12), 1365-1374.
[http://dx.doi.org/10.1001/jama.2010.1361] [PMID: 20858880]
[14]
Levey, A.S.; Stevens, L.A.; Schmid, C.H.; Zhang, Y.L.; Castro, A.F., III; Feldman, H.I.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Greene, T.; Coresh, J. A new equation to estimate glomerular filtration rate. Ann. Intern. Med., 2009, 150(9), 604-612.
[http://dx.doi.org/10.7326/0003-4819-150-9-200905050-00006] [PMID: 19414839]
[15]
Martino, E.; Bartalena, L.; Bogazzi, F.; Braverman, L.E. The effects of amiodarone on the thyroid. Endocr. Rev., 2001, 22(2), 240-254.
[PMID: 11294826]
[16]
Bogazzi, F.; Bartalena, L.; Cosci, C.; Brogioni, S.; Dell’Unto, E.; Grasso, L.; Aghini-Lombardi, F.; Rossi, G.; Pinchera, A.; Braverman, L.E.; Martino, E. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J. Clin. Endocrinol. Metab., 2003, 88(5), 1999-2002.
[http://dx.doi.org/10.1210/jc.2002-021874] [PMID: 12727944]
[17]
Loh, K.C. Amiodarone-induced thyroid disorders: a clinical review. Postgrad. Med. J., 2000, 76(893), 133-140.
[http://dx.doi.org/10.1136/pmj.76.893.133] [PMID: 10684321]
[18]
Grande, D.; Terlizzese, P.; Gioia, M.I.; Parisi, G.; Giagulli, V.A.; Triggiani, V.; Iacoviello, M. New frontiers in the therapeutic approach of patients with cardiovascular and endocrine diseases. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(5), 605-621.
[http://dx.doi.org/10.2174/1871530319666190101151542] [PMID: 30621568]
[19]
Bossone, E.; Arcopinto, M.; Iacoviello, M.; Triggiani, V.; Cacciatore, F.; Maiello, C.; Limongelli, G.; Masarone, D.; Perticone, F.; Sciacqua, A.; Perrone-Filardi, P.; Mancini, A.; Volterrani, M.; Vriz, O.; Castello, R.; Passantino, A.; Campo, M.; Modesti, P.A.; De Giorgi, A.; Monte, I.; Puzzo, A.; Ballotta, A.; Caliendo, L.; D’Assante, R.; Marra, A.M.; Salzano, A.; Suzuki, T.; Cittadini, A. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry. Intern. Emerg. Med., 2018, 13(5), 661-671.
[http://dx.doi.org/10.1007/s11739-018-1844-8] [PMID: 29619769]
[20]
Iovino, M.; Iacoviello, M.; De Pergola, G.; Licchelli, B.; Iovino, E.; Guastamacchia, E.; Giagulli, V.A.; Triggiani, V. Vasopressin in Heart Failure. Endocr. Metab. Immune Disord. Drug Targets, 2018, 18(5), 458-465.
[http://dx.doi.org/10.2174/1871530318666180212095235] [PMID: 29437026]
[21]
Arcopinto, M.; Salzano, A.; Bossone, E.; Ferrara, F.; Bobbio, E.; Sirico, D.; Vriz, O.; De Vincentiis, C.; Matarazzo, M.; Saldamarco, L.; Saccà, F.; Napoli, R.; Iacoviello, M.; Triggiani, V.; Isidori, A.M.; Vigorito, C.; Isgaard, J.; Cittadini, A. Multiple hormone deficiencies in chronic heart failure. Int. J. Cardiol., 2015, 184, 421-423.
[http://dx.doi.org/10.1016/j.ijcard.2015.02.055] [PMID: 25755056]
[22]
Giagulli, V.A.; Guastamacchia, E.; De Pergola, G.; Iacoviello, M.; Triggiani, V. Testosterone deficiency in male: a risk factor for heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 92-99.
[http://dx.doi.org/10.2174/1871530311313010011] [PMID: 23369141]
[23]
De Pergola, G.; Nardecchia, A.; Giagulli, V.A.; Triggiani, V.; Guastamacchia, E.; Minischetti, M.C.; Silvestris, F. Obesity and heart failure. Endocr. Metab. Immune Disord. Drug Targets, 2013, 13(1), 51-57.
[http://dx.doi.org/10.2174/1871530311313010007] [PMID: 23369137]
[24]
Dillmann, W.H. Biochemical basis of thyroid hormone action in the heart. Am. J. Med., 1990, 88(6), 626-630.
[http://dx.doi.org/10.1016/0002-9343(90)90530-Q] [PMID: 2189306]
[25]
Kannan, L.; Shaw, P.A.; Morley, M.P.; Brandimarto, J.; Fang, J.C.; Sweitzer, N.K.; Cappola, T.P.; Cappola, A.R. Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. Circ Heart Fail, 2018, 11(12)e005266
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005266] [PMID: 30562095]
[26]
Selmer, C.; Olesen, J.B.; Hansen, M.L. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J. Clin. Endocrinol. Metab., 2014, 99, 2372-2382.
[27]
Singh, S.; Duggal, J.; Molnar, J.; Maldonado, F.; Barsano, C.P.; Arora, R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int. J. Cardiol., 2008, 125(1), 41-48.
[http://dx.doi.org/10.1016/j.ijcard.2007.02.027] [PMID: 17434631]
[28]
Völzke, H.; Schwahn, C.; Wallaschofski, H.; Dörr, M. Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J. Clin. Endocrinol. Metab., 2007, 92(7), 2421-2429.
[http://dx.doi.org/10.1210/jc.2007-0179] [PMID: 17473067]
[29]
Ochs, N.; Auer, R.; Bauer, D.C.; Nanchen, D.; Gussekloo, J.; Cornuz, J.; Rodondi, N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann. Intern. Med., 2008, 148(11), 832-845.
[http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00225] [PMID: 18490668]
[30]
Nabbout, L.A.; Robbins, R.J. The cardiovascular effects of hyperthyroidism. Methodist DeBakey Cardiovasc. J., 2010, 6(2), 3-8.
[http://dx.doi.org/10.14797/mdcj-6-2-3] [PMID: 20661186]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 3
Year: 2020
Page: [437 - 445]
Pages: 9
DOI: 10.2174/1871530319666191018134524
Price: $65

Article Metrics

PDF: 18
HTML: 2
EPUB: 1
PRC: 1